AIM ImmunoTech (AIM) announced that Paul Goepfert, MD, of the University of Alabama-Birmingham, has agreed to act as the Principal Investigator ...
3d
Vietnam Investment Review on MSNAIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in ...
Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...
1d
Hosted on MSNAIM Vaccine s mRNA RSV Vaccine Approved for U S Clinical TrialsInnovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd. (a joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 6660.HK) ...
5d
Hosted on MSNAIM Vaccine Co., Ltd. Integrates AI for Strategic UpgradeAn update from AIM Vaccine Co., Ltd. Class H ( ($HK:6660) ) is now available. AIM Vaccine Co., Ltd. announced the strategic integration of ...
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 23, 2025, announced that the company is fully ...
As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) ...
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside
Looking ahead, according to the analysis in the FOSUN International Securities research report, AIM Vaccine, as a comprehensive leader in the Chinese vaccine market, demonstrates significant long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results